Alx Oncology (ALXO)CEO sold ~$27K

~$27K

Approx. value · 12K sh @ $2.17

294K

Holds after · shares reported

Traded

Mar 19, 2026

Filed

Mar 23, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jan 21, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“Effective January 21, 2026, the Board of Directors (the “Board”) of ALX Oncology Holdings Inc. (the “Company”) amended the 2025 Inducement Equity Incentive Plan (the “Inducement Plan”) to increase the number of shares reserved for issuance under the Inducement Plan.”
2. Jan 30, 2026Company filing · Form 8-K · Material agreement, Other newsSigned an important agreement, and reported other company news
3. Feb 2, 2026Insider · First buy since 2020Director purchased ~$5M of ALXO shares in the open market
4. Feb 18, 2026InsiderOfficer sold ~$1.3K of ALXO shares in the open market
5. Feb 27, 2026Company filing · Form 8-K · ResultsReported its results
6. Mar 19, 2026 · this disclosureInsiderCEO sold ~$27K of ALXO shares in the open market

What came next

1. Mar 19, 2026InsiderOfficer sold ~$2K of ALXO shares in the open market
2. Apr 13, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“Effective April 13, 2026, the Board of Directors (the “Board”) of ALX Oncology Holdings Inc. (the “Company”) appointed Jeff Knight as Chief Development and Operating Officer.”
3. May 8, 2026Company filing · Form 8-K · ResultsReported its results
4. Jun 25, 2026Company filing · Form 8-K · Material agreement, Agreement endedSigned an important agreement, and ended an important agreement (and 1 more item)
5. Jun 29, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors (and 1 more item)“On June 29, 2026, Corey Goodman, Ph.D. informed ALX Oncology Holdings Inc. (the “Company”) of his resignation as Chairman of the Company’s board of directors (the “Board”) and as a member of the Board, and from all committees thereof, to be effective as of the close of business on June 29, 2026.”
6. Jul 1, 2026InsiderOfficer sold ~$2.9K of ALXO shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Alx Oncology

For Alx Oncology, OQRO holds 2 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ALXO page.

Other recent filings by Jason Lettmann, CHIEF EXECUTIVE OFFICER

• SEC Form 4 at Alx Oncology (ALXO)Aug 18, 2026
• SEC Form 4 at Alx Oncology (ALXO)Sep 18, 2025
• SEC Form 4 at Alx Oncology (ALXO)Sep 18, 2025
• SEC Form 4 at Alx Oncology (ALXO)Aug 19, 2025
• SEC Form 4 at Alx Oncology (ALXO)Feb 21, 2025

The full history of Jason Lettmann, CHIEF EXECUTIVE OFFICER is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Alx Oncology

• SEC Form 4Aug 18, 2026
• SEC Form 4Aug 18, 2026
• SEC Form 4Jul 6, 2026
• SEC Form 13F-HRMay 15, 2026
• SEC Form 4Mar 23, 2026
• SEC Form 4Feb 20, 2026

Everything OQRO holds on this company is on its ALXO page.